Abingdon Health PLC
08 September 2026
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Shareholder open day
York, UK and Madison, WI, USA, 8 September 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it will hold an Open Day for shareholders at the Company's headquarters in York on Wednesday 21 October 2026 from 11am to 2pm.
The day will provide an opportunity for shareholders to meet the Senior Management team, take a tour of the facility and familiarise themselves with the Company's products and services.
Availability is limited so please contact Walbrook PR via abingdon@walbrookpr.com or call 020 7933 8780 to reserve a place.
For those that are unable to make it in person, a recording of the presentation will be made available on the Company's website shortly after the event. Questions can be pre-submitted in advance of the meeting via abingdon@walbrookpr.com and answers, where appropriate, will be addressed in the presentation.
Any shareholders wishing to keep up to date with Abingdon Health news, please email abingdon@walbrookpr.com
Enquiries:
|
Abingdon Health plc |
||
|
Chris Hand, Executive Chairman |
Via Walbrook PR |
|
|
Tom Hayes, CFO |
||
|
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser) |
Tel: +44 (0)20 7220 0500 |
|
|
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales) |
||
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Abingdon Health
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.
Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.
LEI - 213800XFI4WV3FBILO20
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.